Drug Profile
Embryonic-like human extracellular matrix - Histogen
Alternative Names: hECM - HistogenLatest Information Update: 18 Mar 2024
Price :
$50
*
At a glance
- Originator Histogen
- Class Antineoplastics; Extracellular matrix proteins
- Mechanism of Action Apoptosis stimulants; Caspase 9 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 14 Dec 2023 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Cancer in USA
- 12 Aug 2016 Embryonic-like human extracellular matrix - Histogen is available for licensing as of 12 Aug 2016. http://www.histogen.com/